Evidence map›Paper›PMID 35934060›Full record

ArticleGastroenterology2022

HNF4A Defines Molecular Subtypes and Vulnerability to Transforming Growth Factor β-Pathway Targeted Therapies in Cancers of the Distal Esophagus.

Andrew E Blum, Durgadevi Ravillah, Betrnet Consortium, Ramachandra M Katabathula, Sirvan Khalighi, Vinay Varadan, Kishore Guda

Abstract read
In one paragraph

Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew E BlumDivision of Gastroenterology, Northeast Ohio Veteran Affairs Healthcare System, Cleveland, Ohio,; Division of General Medical Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, and, Digestive Health Research Institute, Case Western Reserve University School of Medicine, Cleveland, Ohio. Electronic address: andrew.blum@case.edu.
Durgadevi RavillahDivision of General Medical Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Betrnet Consortium
Ramachandra M KatabathulaDivision of General Medical Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Sirvan KhalighiDivision of General Medical Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Vinay VaradanDivision of General Medical Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Kishore GudaDivision of General Medical Sciences-Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, and, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio. Electronic address: kkg5@case.edu.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI AMITABH CHAK · 2015 to 2026
$15.6M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
Identify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7M
EPHA6 as a novel candidate driver gene in colon cancerR01CA204549 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GUDA, KISHORE · 2016 to 2020
$1.8M
Systems biology frameworks to unravel mechanisms driving complex disordersK25DK115904 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI VARADAN, VINAY · 2019 to 2021
$515k
TGFβ and Smad Signaling Components in Esophageal AdenocarcinomaIK2CX001831 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI Andrew Edward Blum · 2020 to 2026
–
CSRD VA IK2 CX001831NCI NIH HHS P30 CA043703NCI NIH HHS P50 CA150964NCI NIH HHS R01 CA204549NCI NIH HHS U01 CA152756NCI NIH HHS U54 CA163060NIDDK NIH HHS K25 DK115904NIDDK NIH HHS P30 DK097948
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsTransforming Growth Factor betaEsophagusHepatocyte Nuclear Factor 4HumansHepatocyte Nuclear Factor 4HNF4A protein, humanTransforming Growth Factor beta

Identifiers

PMID35934060
PMCPMC9613531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.